USA flag logo/image

An Official Website of the United States Government

HIV Therapeutic Vaccine Concept

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93356
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI078861
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARIAVAX, INC.
708 Quince Orchard Road Suite 205 Gaithersburg, MD 20878
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: HIV Therapeutic Vaccine Concept
Agency: HHS
Contract: 1R43AI078861-01A2
Award Amount: $299,504.00
 

Abstract:

DESCRIPTION (provided by applicant): The bridging sheet in HIV-1 gp120 connects the inner domain with the outer domain of gp120. Half of the bridging sheet ( 2/3) is composed of amino acids from the variable segments from the V2 and V3 domains whereas the second half of the bridging sheet, referred to as 20/21, is composed of highly conserved amino acids from the C4 domain. 20/21 is a major component of the CD4 binding site (CD4bs) in gp120 and, when it is not occupied by CD4, appears to be accessible to binding antibodies. Within the first 3 to 4 months of HIV infection, antibodies to the conformationally constrained 20/21 are not produced, making 20/21 a possible target for early stage therapeutic vaccine intervention. We have successfully designed and synthesized an immunogen from the 20/21 amino acid sequence, called CDC4, and immunized test animals to evaluate the targeted antibodies for effectiveness in binding to gp120 from various strains of the virus. The aim is to develop CDC4 as a component of a therapeutic vaccine for suppressing the spread of HIV in vivo. The goal of this proposal is to tag with antibodies the 20/21 portion of the bridging sheet expressed on the surface of HIV-infected cells. In vitro neutralization assays and tests with the antibodies capable of activating antibody-dependent cellular cytotoxicity (ADCC) as a possible correlate of in vivo neutralization will be performed. Simple binding of anti- 20/21 antibodies to gp120 and activating ADCC-like mechanisms then might act to control viral spread and perhaps delay the need of an infected patient having to take anti HIV-1 drugs. PUBLIC HEALTH RELEVANCE: This project is geared toward creating a novel therapeutic vaccine against a conserved sites on the surface of HIV-1. Such a no vel immunotherapeutic should be useful in assisting patients suffering from HIV infection with keeping the virus under control.

Principal Investigator:

Frank A. Robey
2406322789
FROBEY@ARIAVAX.COM

Business Contact:

Frank A. Robey
frobey@ariavax.com
Small Business Information at Submission:

ARIAVAX, INC.
708 Quince Orchard Road Suite 205 Gaithersburg, MD 20878

EIN/Tax ID: 522326239
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No